Forskolin

製品コードS2449 別名:Coleonol

Forskolin化学構造

分子量(MW):410.5

Forskolin is a ubiquitous activator of eukaryotic adenylyl cyclase (AC) in a wide variety of cell types, commonly used to raise levels of cAMP in the study and research of cell physiology.

サイズ 価格(税別)  
JPY 23240.00
JPY 18260.00
JPY 44820.00
JPY 61420.00
JPY 94620.00

カスタマーフィードバック(3)

  • Eur J Cancer 2014 50(7), 1310-20. Forskolin purchased from Selleck.

    Western blot analysis shows pERK levels after 8 hours treatment with forskolin. AC activation with 10 μmol/L forskolin (F).

    Mol Cancer Res, 2017, 15(12):1792-1802. Forskolin purchased from Selleck.

  • Measurement of cAMP accumulation in INS-1 cells. (A) INS-1, or (B) INS-1 transfected with murine GPR109A for 24 h, or (C) INS-1 transfected with human GPR109A for 24 h were incubated in DMEM (2.5 mM glucose) media with or without PTX (100 ng/ml) for 24 h. Cells were then incubated in KRB supplemented with 2.5 mM glucose, 500 μM IBMX, 10 μM forskolin, and with/without 10 or 100 μM NA for 1 h. After lysis with HCl (0.1 M), cells were sonicated and spun. The supernatants were saved for cAMP measurement by ELISA. (D) Reduction of cAMP accumulation in INS-1 and INS-1 cells transfected with GPR109A in the presence of 10 or 100 μM NA. White bar: INS-1 cells, grey bar: INS-1 cells transfected with murine GPR109A; black bar: INS-1 cells transfected with human GPR109A. (∗ and #p < 0.05, ∗ and ##p < 0.001). (n = 5).

    Gen Comp Endocrinol, 2016, 237:98-108. Forskolin purchased from Selleck.

製品安全説明書

cAMP阻害剤の選択性比較

生物活性

製品説明 Forskolin is a ubiquitous activator of eukaryotic adenylyl cyclase (AC) in a wide variety of cell types, commonly used to raise levels of cAMP in the study and research of cell physiology.
ターゲット
Adenylyl cyclase (AC) [1]
(A wide variety of cell types)
体外試験

Forskolin increases cAMP levels in preparations of membranes, cells, or tissues. Forskolin not only activates AC but also interacts with certain other proteins, including glucose transporters and ion channels. Forskolin is able to promote activation of nine different transmembrane iso-forms of AC, albeit with somewhat less efficacy for AC9, which could be used to provides a means to identify and quantify high-affinity binding sites, i.e., G-proteins (Gs)–AC complexes. Activation of s by GPCRs contributes to Forskolin-stimulated cAMP generation in cells because of s-Forskolin potentiation of AC activity. [1] Forskolin stimulates adenylate cyclase activity without interacting with cell surface receptors. Forskolin's potentiation of cAMP in turn inhibits basophil and mast cell degranulation and histamine release, lowers blood pressure and intraocular pressure, inhibits platelet aggregation, promotes vasodilation, bronchodilation, and thyroid hormone secretion, and stimulates lipolysis in fat cells. Forskolin inhibits the binding of platelet-activating factor (PAF), independently of cAMP formation, which may be a result of Forskolin's direct effect on PAF or via interference with PAF binding to receptor sites. Forskolin also appears to have an effect on several membrane transport proteins, and inhibits glucose transport in erythrocytes, adipocytes, platelets, and other cells. Forskolin is used to treat with glaucoma. [2]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HEK293 Ml\wSpVv[3Srb36gRZN{[Xl? NWfwem9NOTBizszN MV22JIg> NWXtbFRDcW6lcnXhd4V{KHCqb4PwbI9zgWyjdHnvckBw\iCxdnXy[ZhxemW|c3XkJGtNUEx|IHH0JHM1OzN? NHn6Z5MzPjR|NUS5PC=>
Mo-DCs MWHGeY5kfGmxbjDBd5NigQ>? Mk\OOVAh|ryP NF\sPG4zPOLCiXi= M332ZZBzd22xdHXzJGlNNTJ|IIDyc4R2[3Srb36gbY4hfGinIIP1dIVzdmG2YX70JI9nKHq7bX;zZY4he3SrbYXsZZRm\CCPbz3ER5PDqA>? MnfMNlY1OTJ7NEi=
RBMECs  MXvGeY5kfGmxbjDBd5NigQ>? M2\QVlXDqM7:TR?= M1vtS|HDqGh? MlvHZoxw[2u|IITo[UBT[WNzIHnuZYN1cX[jdHnvckBqdmS3Y3XkJIJ6KEWPQWCtTWk> MWiyOlM2QDB|OR?=
INA-6 MVTD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MWqwMVExOCEQvF2= NFPu[|A4OuLCiXi= NEPiN4FqdmS3Y3XzJINmdGxiZHXheIgh\G:|ZTDk[ZBmdmSnboTsfS=> NHrobmkzPjNyNk[yOC=>
OPM-2 MVnD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NFrqdHkxNTFyMDFOwG0> NV7iNGxqPzMkgJno M4TF[Ilv\HWlZYOgZ4VtdCCmZXH0bEBld3OnIHTldIVv\GWwdHz5 M2fGelI3OzB4NkK0
U266 MnnTR4VtdCCYaXHibYxqfHliQYPzZZk> M3;ueFAuOTByIN88US=> NITFZ3g4OuLCiXi= NGftS5lqdmS3Y3XzJINmdGxiZHXheIgh\G:|ZTDk[ZBmdmSnboTsfS=> NYPTWXRuOjZ|ME[2NlQ>
H929 M{DsRWNmdGxiVnnhZoltcXS7IFHzd4F6 Mn7mNE0yODBizszN MkTDO|LjiImq NYnES4VMcW6mdXPld{Bk\WyuIHTlZZRpKGSxc3Wg[IVx\W6mZX70cJk> MlL2NlY{ODZ4MkS=
RPMI 8226 MWjD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MYewMVExOCEQvF2= NYHtWJpTPzMkgJno MWjpcoR2[2W|IHPlcIwh\GWjdHig[I9{\SCmZYDlcoRmdnSueR?= NGi2SYIzPjNyNk[yOC=>
MDCK  NYLFd4FSTnWwY4Tpc44hSXO|YYm= NUXi[YJQOTBiwsXN NVzTWm0{OjRiaB?= NF3QcJVFVVOR NH3JTmJ2eHKnZ4XsZZRmeyC2aHWg[ZhxemW|c3nvckBw\iCWR1[t{tIyKGGwZDDDWGdHyqB? MmPRNlYzODJ|NUK=
MDCK  MVPGeY5kfGmxbjDBd5NigQ>? NV\q[odFOTBiwsXN MnW5NlQhcA>? M1HWeWROW09? Mn73bY5pcWKrdIOgeIhmKGmwY4LlZZNm\CCneIDy[ZN{cW:wIH;mJGZPKGOjdYPl[EBjgSCWR1[t{tIy MlrWNlYzODJ|NUK=
Spinal cords  MX3GeY5kfGmxbjDBd5NigQ>? MWexxsDPxE1? M3jVdFMxKG2rbh?= MkXnd5RqdXWuYYTld{BkSU2SIHzleoVtew>? M13mflI3OTJ4OUK2
BeWo  MYrGeY5kfGmxbjDBd5NigQ>? M1TON|I26oDLzszN M{mzcFI1NzR6L{eyJIg> Mlm2cIVi\HNidH:gZY4hcW6lcnXhd4UhcW5idHjlJIV5eHKnc4Ppc44hd2Zib4To[ZIh\nW|aX;uJI1iemuncoO= NEfHemUzPjB3M{W0PS=>
bovine oocytes M1fJbWZ2dmO2aX;uJGF{e2G7 MU[xNFDDqM7:TR?= NHLPVIcyOsLiaB?= M2HHO4lvcGmkaYTzJJRp\SCnZn\lZ5Qhd2ZiTmDQRUBidmRxb4KgUnBRSyC2bzDzeIlufWyjdHWgdoV{fW2ydHnvckBw\iCvZXnvd4l{ M2q2NFI3ODVzNkGx
Caco-2  M{LsWWZ2dmO2aX;uJGF{e2G7 MmnRNE4yNzFxMUCg{txO NX21R4dxOjEEoH3pci=> M3:zWolv\HWlZYOgZUBld3OnLXTldIVv\GWwdDDpcoNz\WG|ZTDpckBqdnS{YXPlcIx2dGG{IHPBUXAhdGW4ZXzz NX;Wc3BXOjZyNEmxNFI>
Caco-2  MlXYSpVv[3Srb36gRZN{[Xl? M2LCV|AvOS9zL{GwJO69VQ>? MkK5NlQhcA>? MmDobY5kemWjc3XzJG1TWDJicILveIVqdiCuZY\lcC=> MWeyOlA1QTFyMh?=
AML-12  NU\pZ3dvTnWwY4Tpc44hSXO|YYm= NV7hW4lnOjBizszN M4\OPFMhcA>? Moj4eZBz\We3bHH0[ZMhfGinIIDoc5NxcG:{eXzheIlwdiCuZY\lcJMh[XRiVHjyMVQyOSCjbnSgV4VzNTR7Mx?= MXKyOlA1QDl6NR?=
AML-12  MWrGeY5kfGmxbjDBd5NigQ>? NIHrbVQzOCEQvF2= M3PzTlEuQCCq NH7LTWxqdmO{ZXHz[ZMh\2y3Y3;z[UBxem:mdXP0bY9v M1jmPFI3ODR6OUi1
AML-12  M4LyV2Z2dmO2aX;uJGF{e2G7 M{Sxd|IxKM7:TR?= M{noZVMhcA>? Ml3qeZAuemWpdXzheIV{yqCSZ3OxZUzDqFCncHPrMEBidmUEoFe2dIPDqG2UTlGgcIV3\Wy| MnLRNlYxPDh7OEW=
AML-12  NInwdGhHfW6ldHnvckBCe3OjeR?= NH;1Z|AzOCEQvF2= M3rnbFMhcA>? NIH3dnVqdmS3Y3XzJJRp\SCmZYDoc5NxcG:{eXzheIlwdiCxZjDDVnREOsLi NUHzUpQ3OjZyNEi5PFU>
RBMECs NXHxXpRvTnWwY4Tpc44hSXO|YYm= NVficmhkPcLizszN NILBVWMyKGh? M{HjUYlvcGmkaYTzJGVOSVBvSVmtbY5lfWOnZDDpcoFkfGm4YYTpc44hd2ZiUnHwNeKh MmXQNlYxPDR4NkO=
EndoC-βH1 MWTGeY5kfGmxbjDBd5NigQ>? MlTLOeKh|ryP NUDS[lFnOSCq NHTNdXNxd3SnboTpZZRmeyCpbIXjc5NmNWmwZIXj[YQhcW6|dXzpckB{\WO{ZYTpc44hcW5idHjlJJBz\XOnbnPlJI9nKGeudXPvd4U> NX;3bVluOjZyMki1OlI>
EndoC-βH1 NUXNXJJUTnWwY4Tpc44hSXO|YYm= MlLZOeKh|ryP NFLaS2oyKGh? MkHScIVi\HNidH:gZUB{fHKxbnegZ2FOWCCrbnPy[YF{\Q>? M{PrRVI3ODJ6NU[y
SH-SY5Y NEm0e3pHfW6ldHnvckBCe3OjeR?= MVizNEDPxE1? NG\iSmU{OCCvaX6= M{m4OWROW09? MVfzbYdvcW[rY3HueIx6KGmwY4LlZZNmeyC2aHWgZYN1cX[jdHnvckBw\iCSS1G= MWWyOlAzPTF|Nx?=
PC-3 NY\4OIVtTnWwY4Tpc44hSXO|YYm= M1exXFQxKML3TR?= M4i5XFIhcA>? MnO2SG1UVw>? M1T2OIxm[WS|IITvJHBROkFiYXP0bZZifGmxbh?= NWrpXFdtOjZyMkO4N|Y>
PC-3 NWqzRnZ7S2WubDDWbYFjcWyrdImgRZN{[Xl? M3;Pe|QxKML3TR?= MmPxNlQwPDhxN{KgbC=> M2fBdmROW09? M{XzSoRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTD0bY1mKGSncHXu[IVvfGy7 M4X3XVI3ODJ|OEO2
SCG MXTGeY5kfGmxbjDBd5NigQ>? MWSyNEDPxE4EoB?= NXHL[XRKTE2VTx?= M3zqU5JmfmW{c3nicJkhe3WycILld5NmeyCLS2[ge4l1cCCjIFnDOVAhd2ZiMkSuOEDPxE1? M2\oNlI2QTZ{MUOy
HEK-293 M4XzfmZ2dmO2aX;uJGF{e2G7 MXKzOUDPxE4EoB?= MljNSG1UVw>? NVr5NWNPcW6mdXPld{BiKGOxboPwbYN2d3W|IPMAoIlv[WO2aY\heIlwduLCnTDv[kB1cGViS4[yMlEh[3W{cnXueC=> MWKyOVk3OjF|Mh?=
SCG M4TqeWZ2dmO2aX;uJGF{e2G7 NXyyV4xZOTByIN88UeKh MlXZSG1UVw>? Mn7BdoVlfWOnczD0bIUh\XilaYThZoltcXS7IH;mJHNETyCwZYXyc45{ M{LKPFI2QTZ{MUOy
PCCL3 Mof2SpVv[3Srb36gRZN{[Xl? NGHUVW0yOCEEtV2= NVmwSlFlOjRiaB?= MYrlcohidmOnczDEeW95OiCycn;tc5RmeiC2cnHud4NzcXC2aX;uJIFkfGm4aYT5xsDjiIt? NXfSOWs5OjV7NkC5OVY>
3T3-L1 preadipocytes Ml;USpVv[3Srb36gRZN{[Xl? NUjaS|l{OTBizszNxsA> M{LPSFEzKGh? NXnnVZNYcW6mdXPld{BEWkWEIIDoc5NxcG:{eXzheIlwdiCjbnSgR{9GSlEQsjDlfJBz\XO|aX;u MnziNlU6OjhyNUi=
H295R  NEHRd2ZHfW6ldHnvckBCe3OjeR?= M17ZW|ExyqEQvF2= NHvUW2I1QMLiaB?= M4PKN4lv[3KnYYPld{B{fGW{b3nkJI1mfGGkb3zpeIV{KGmwIITo[UBidmS{b3flckwhdWmwZYLhcI8uKGGwZDDncJVkd2OxcoTpZ49q\CCyYYToe4F6ew>? NVXn[YVnOjV6Nkm1OVY>
PBMC NVnuTod6TnWwY4Tpc44hSXO|YYm= MlL3OVDDqM7:TR?= M3vOO|I1yqCqwrC= NXLzVJJxcW6qaXLpeJMhfGinIHnuZ5Jm[XOnZDDz[YNz\XSrb36gc4YhXE6IIHnu[JVk\WRiYomgeIhmKESSRR?= MoruNlU5PjZyN{m=
GLUTag  NHjGXYNHfW6ldHnvckBCe3OjeR?= M2rOXFEx6oDLwsXN NHWxN2wxNzJxNDDo M4XrSpN1cW23bHH0[ZMhT0ySLUGgd4VkemW2aX;uJINwfHKnYYTl[EB4cXSqIFnCUXg> NFXXXGczPTh|Mk[zNS=>
GLUTag  MXzGeY5kfGmxbjDBd5NigQ>? MmrMNVDjiIoEtV2= NHzEXpk1KGh? MV7pcoNz\WG|ZYOgeIhmKHCFUlXCJIxmfmWuczD3bZRpKHSqZTDJRm1Z NXThcXN3OjV6M{K2N|E>
BAECs NWfiNI57TnWwY4Tpc44hSXO|YYm= M3zoWVI2KM7:TR?= M1TGbVI1KGh? MWflcohidmOnczD0bIUh[WO2aY\heIlwdiCxZjDQVGFT|rFiYomgOUDPxE1icnXzeoVz[XS{b3ysJHQ1UFNuIH;yJFQuWEGS NXXuXIRMOjV5OUi4NlY>
PC12 NVPiS3BHTnWwY4Tpc44hSXO|YYm= NXnGeWFGOjYEoN88US=> MnPiOFghcA>? NV60Vmc1[WO2aY\heIV{KGODTWC= NUDsSlJxOjV5NkmzNFU>
GH3 NXzDU|FjTnWwY4Tpc44hSXO|YYm= M2n5ZVHDqM7:TR?= M4PrO|YucA>? MkmzZZR1\W63YYTld{B1cGViY3;ydoVt[XSrb36gZoV1f2WnbjDQVmwh[W6mIFLtZYwyKGW6cILld5Nqd25? MWeyOVczPzBzOB?=
GH3 MkTZSpVv[3Srb36gRZN{[Xl? NFLvbGwyyqEQvF2= M{PjelYucA>? NYPIUJZ4cW6mdXPld{BRWkxiYX7kJGJu[WxzLDDieZQhdm:2IFPsc4NsNCCvUl7BJIV5eHKnc4Ppc44> MWWyOVczPzBzOB?=
BeWo M4XVXmZ2dmO2aX;uJGF{e2G7 M1;WTVEx6oDMzszNxsA> MnPVO|IhcA>? NXXqd|BETE2VTx?= MXrt[YRq[XSnczDC[XdwKGOnbHyg[Iln\mW{ZX70bYF1cW:w NHrIWHUzPTdzM{SyOS=>
oocytes Mn3mSpVv[3Srb36gRZN{[Xl? NUD3cXBMPSEQvF2= M3HjPFI1KGh? NXy0cY92[XS2ZX71ZZRmeyC{aD3pcpN2dGmwIHHjeIlwdiCxbjDvc4N6fGViR2\CSEB{cWewaX\pZ4FvfGy7wrC= NYjMVndbOjV5MEe4OVQ>
SC NYn4SGduTnWwY4Tpc44hSXO|YYm= MoftNE42KM7:TR?= NEnLblkzPCCq NHO5PJJucW2rY3vzJJRp\SCnZn\lZ5Qhd2ZiY1HNVEBidmGub3fzJI9vKE9zIHHu[EBOSlBiZYjwdoV{e2mxbh?= Mle2NlU4ODV6N{S=
SC M{fQS2Z2dmO2aX;uJGF{e2G7 MlP2NE42KM7:TR?= MVu3NkBp MlPIbY5kemWjc3XzJIJwfGhiS4LvfE0zOCCjbnSgU|Eh\XiycnXzd4lwdiCrbjDhfI9vNXKnbHH0[YQhW0O|IHL1eEBwdmy7IFvyc5guOjEEoB?= MYeyOVcxPTh5NB?=
UACC-647  M{i5UWZ2dmO2aX;uJGF{e2G7 MYfEUXNQ MUfs[YFleyC2bzDhJJJqe2ViaX6gZ2FOWCCuZY\lcJMhMEWFNUFCpF3DqDJyLkO5xsDPxE1r NFzyOWEzPTdyM{CyOS=>
UACC-647  MUHGeY5kfGmxbjDBd5NigQ>? M3zrfVExyqEQvF2= NV\HdoFIOTVibXnu M1PYeWROW09? M1XVdIlvcGmkaYTzJGVTUyCyaH;zdIhwenmuYYTpc44> NUH4RpU2OjV5MEOwNlU>
UACC-647  NVfwVHl2TnWwY4Tpc44hSXO|YYm= MkPZNVDDqM7:TR?= NHjvN3gyPSCvaX6= M{fWOGROW09? MoXCbY5kemWjc3XzJIVGTjJicHjvd5Bpd3K7bHH0bY9vKGyndnXsd:Kh NEnpUGszPTdyM{CyOS=>
SH-SY5Y  MVrGeY5kfGmxbjDBd5NigQ>? NVnGT2NpOTEEoN88US=> M175TVHDqGkEoB?= MW\pcoNz\WG|ZYOgUHVEKGGldHn2bZR6 NY\CcJB2OjV3OUe0N|M>
SH-SY5Y  M3\md2Z2dmO2aX;uJGF{e2G7 NHm2bo0yOMLizszN MmnUNeKhcMLi MWXpcoNz\WG|ZYOgRWdEOSCvUl7BJIxmfmWu NVvSb3FGOjV3OUe0N|M>
hADSCs M3zFU2Z2dmO2aX;uJGF{e2G7 NXjSOlNQPeLCidM1US=> M4TGS|MxKG2rbh?= MlLXbY5kemWjc3XzJINCVVBibHX2[Yx{ MWqyOVU6OTlyOB?=
HEK293  NFHIXpdHfW6ldHnvckBCe3OjeR?= NUHPenlmPeLCidM1US=> NET1Nok{OCCvaX6= M3KybIlv[3KnYYPld{BkSU2SIHzleoVtew>? NVjFVph{OjV3OUG5NFg>
3T3-L1 NWrKPY1GTnWwY4Tpc44hSXO|YYm= MX[yMlUwPSEQvF2= NGfmVYozPCCqwrC= NGDOS5B{cWewaX\pZ4FvfGy7IHTlZ5Jm[XOnczDBWGdNKHC{b4TlbY4h\XiycnXzd4lwdiCjdDDhcIwh\G:|ZYOgeIV{fGWm MWSyOVU6ODV7Nx?=
OCI-Ly1  MnvJSpVv[3Srb36gRZN{[Xl? M3P6cVQxyqEQvF2= NFvNV2oyyqCqwrC= M{fJO2ROW09? MnrtbY5lfWOnczD0bIUhcW6lcnXt[Y51KG:oIHPBUXAh[2:wY3XueJJifGmxboO= MV:yOVU4PjJ{MB?=
OCI-Ly18  NVHYdVBmTnWwY4Tpc44hSXO|YYm= NY\wdo0yPDEEoN88US=> M2Du[FHDqGkEoB?= NGrwTFBFVVOR M3W3Nolv\HWlZYOgeIhmKGmwY4LlcYVvfCCxZjDjRW1RKGOxbnPlcpRz[XSrb37z MmnHNlU2PzZ{MkC=
BeWo MoPZSpVv[3Srb36gRZN{[Xl? NUDxRZRUOjEEoNM1US=> M3TX[|Q5yqCq M4C4c2ROW09? M{PI[olv[3KnYYPld{B1cGViZHnm[oVz\W62aXH0bY9vKG:oIFLlW48h[2WubIO= NFjNbVEzPTV4Nke0NC=>
BeWo MWnGeY5kfGmxbjDBd5NigQ>? M4K0cFIxyqEEtV2= M3G2RlQ5yqCq M1HwOmROW09? NWTO[VZYcW6lcnXhd4V{KHSqZTDh[Ihme2mxbjDv[kBVUFBvMTDtc45w[3m2ZYO= M4\4cVI2PTZ4N{Sw
LNCaP  MXfGeY5kfGmxbjDBd5NigQ>? MmG1NVDDqM7:TR?= NXfLSXJEOTJiaNMg MVzEUXNQ NULCeGQ6cW6mdXPld{BiKGS{YX3heIlkKGmwY4LlZZNmKG:oIFPSSWIyKGGldHn2bZR6 MXuyOVU1QDB7OR?=
ThGCs  NYfvVXBFTnWwY4Tpc44hSXO|YYm= Ml70NVDjiIsQvF2= MnPSOQKBkmh? M1HjUoF2\22nboTzJGhKTjGDIHzleoVteyC2aHH0JJdmemVic4TpcZVt[XSnZDDifUBEd0OuMh?= MXGyOVQ{OzB{Nx?=
ThGCs  NEm1XmhHfW6ldHnvckBCe3OjeR?= M1LSVlEx6oDMzszN NXPES5h4POLCini= MUPpcoNz\WG|ZYOgR49EdDJvaX7keYNm\CCHRF6yxsBo\W6nIHX4dJJme3Orb36= M1PsXFI2PDN|MEK3
ThGCs  MWfGeY5kfGmxbjDBd5NigQ>? NVSxNHNZOTEkgJtOwG0> M2S2RlMhcA>? MUfpcohq[mm2czD0bIUh\W[oZXP0JI9nKEh{T{Kgc44hTUSQMjDtVm5C M4nROlI2PDN|MEK3
RBMECs M13GOWZ2dmO2aX;uJGF{e2G7 MWCwMlA2NzBwNT:1JO69VQ>? M4nkclAvOjViaB?= MoPvbY5kemWjc3XzJINCVVBiY3;uZ4VvfHKjdHnvci=> NXjIc|ZtOjV2MU[2OVE>
RBMECs NGDicFFHfW6ldHnvckBCe3OjeR?= NYLKOZduPcLizszN NXLjN2FYOSCq M4rxbYJtd2OtczD0bIUh[WO2aY\heIlwdiCxZjDSbI9CN1KRQ1ugbY5lfWOnZDDifUBGVUGSLVnJ M2fj[VI2PDF4NkWx
RBMECs NIfUeVhHfW6ldHnvckBCe3OjeR?= M2O5VFXDqM7:TR?= M4Py[FEhcA>? M1zDWJBz\X[nboTzJJRp\SCHTVHQMWlKNWmwZIXj[YQhXEWHUjD2ZYx2\SCmZXPy[YF{\Q>? NWXGdlRuOjV2MU[2OVE>
RBMECs M{f2PGZ2dmO2aX;uJGF{e2G7 M{mxflXDqM7:TR?= M4rxeFEhcA>? NUTEeIhCeHKndnXueJMhfGinIHnuZ5Jm[XOnIHnuJGhTWCCobIX4JIFkem:|czD0bIUhSlSEIHnu[JVk\WRiYomgJGVOSVBvSVm= MnTRNlU1OTZ4NUG=
RBMECs NUnUfI1pTnWwY4Tpc44hSXO|YYm= NXjGV5JsPcLizszN NHzxOYMyKGh? NF:5WGhqdmirYnn0d{B1cGViZHXjdoVie2WmIH;mJIFud3WwdDDv[kBbVy1zIHnuJG1HeyCrbnT1Z4VlKGK7IFXNRXAuUUl? MVqyOVQyPjZ3MR?=
RBMECs NGrNUZBHfW6ldHnvckBCe3OjeR?= NIr0[WI2yqEQvF2= MVKxJIg> NUD0SWMxemW4ZYLz[ZMhfGinIHPoZY5o\XNiaX6gXm8uOSCmaYP0doljfXSrb36gd4VmdiC5aYToJGVOSVBvSVmgeJJm[XSvZX70 MknCNlU1OTZ4NUG=
RBMECs MoC5SpVv[3Srb36gRZN{[Xl? MWm1xsDPxE1? NYn2cXFYOSCq NIKwVGJjdG:la4OgeIhmKEWPQWCtTWkucW6mdXPl[EBkcGGwZ3WgbY4hVUyFIIDoc5NxcG:{eXzheIlwdg>? NGDMUZAzPTRzNk[1NS=>
RBMECs MWXGeY5kfGmxbjDBd5NigQ>? M2\KOFXDqM7:TR?= MVexJIg> NELCSJdjdG:la4OgeIhmKGGldHnuJIN6fG:|a3Xs[ZRwdiC{ZXHydoFv\2WvZX70JJNm\W5id3n0bEBGVUGSLVnJJJRz\WG2bXXueOKh MVyyOVQyPjZ3MR?=
Primary bovine chondrocytes NH7tTFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\vc2U2|ryP MnPVOFghcA>? MV\y[ZZmenOnczD0bIUhcW6qaXLpeI9zgSCnZn\lZ5Qhd2ZiY3Xs[YNwgGmkIH;uJJBzd2yrZnXyZZRqd25iaX6g[5Jwf3SqIIDsZZRmKGOqb37kdo9kgXSncx?= M{iyeVI2PDB4MEG2
EM1  NU\3fINpTnWwY4Tpc44hSXO|YYm= M2nseFE26oDMzszN MVi0PEBp MkjPdoVlfWOnczD0bIUh\XiycnXzd4lwdiCxZtMgUGlHyqCxctMgVHRIWzMEoHnuxsBESUyULTDvduKhTVCDQ{Ktd4lt\W6lZXSgSW0yKGOnbHzzxsA> M1XzVVI2Ozd6Nk[x
BeWo  NGfm[GZHfW6ldHnvckBCe3OjeR?= NEXWdVMzOMLiwsXN NUjic5Y1PDkEoHlCpC=> MWLEUXNQyqB? M33ydIlv[3KnYYPld{B1cGViYnX0ZU1pS0dicnXs[YF{\Q>? MYeyOVM3OjJ4MB?=
BeWo  MYLGeY5kfGmxbjDBd5NigQ>? MnfmNlDDqML3TR?= MWG0POKhcMLi MYPEUXNQyqB? NGC4[VNld3ewcnXneYxifGW|IITo[UBt\X[nbDDv[kBVVUWPRkG2 MYCyOVM3OjJ4MB?=
BeWo  MYDGeY5kfGmxbjDBd5NigQ>? Mnf0NlDDqML3TR?= MUK0POKhcMLi M{DreWROW00EoB?= MX\kc5dvemWpdXzheIV{KHSqZTDs[ZZmdCCxZjDHR20uOQ>? MkLPNlU{PjJ{NkC=
granulosa cells MYHGeY5kfGmxbjDBd5NigQ>? M{Cz[FExKM7:TR?= Mk\hNVIwOjRiaB?= NInaSmxqdmO{ZXHz[ZMhfGinIHzleoVteyCxZtMgVmdUOsLibWLORS=> MneyNlU{OzlzMEW=
granulosa cells NF7hc4JHfW6ldHnvckBCe3OjeR?= NF\GdG4yOCEQvF2= M4jLTFEzNzJ2IHi= NV61R5RscW6lcnXhd4V{KHSqZTDs[ZZmdHNib3[gdoVxd3K2ZYKgZYN1cX[rdImg[o9zKHSqZTDsc45o\XO2IH\yZYdu\W62IDlijLI5PTRxK{G4VmdUOi6OVVOp M3PJTFI2OzN7MUC1
granulosa cells Ml;tSpVv[3Srb36gRZN{[Xl? MV6xNEDPxE1? MWCyOEBp NF7kOnRqdmO{ZXHz[ZMhfGinIHnueIVve2m2eTDv[kBFVkFxcILveIVqdiClb33wcIV5 M2rMbVI2OzN7MUC1
granulosa cells NFf5TGlHfW6ldHnvckBCe3OjeR?= MXOxNEDPxE1? NYm5bFA6OjRiaB?= NX3uSoU4cW6lcnXhd4V{KHSqZTDs[ZZmdHNib3[gVmdUOiCycn;tc5RmeiCjY4Tpeol1gQ>? M1fKbVI2OzN7MUC1
SK-N-AS  NELScGFE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MWixNEDPxE4EoB?= NGjXXmQzPC92ODDo NXrTTnJs\W6qYX7j[ZMhfGmvZT3k[ZBmdmSnboTsfUBk\WyudXzhdkB3cWGkaXzpeJnDqA>? MUWyOVI3PjB4Mx?=
SK-N-AS  MYLGeY5kfGmxbjDBd5NigQ>? NIH0fncyOCEQvF5CpC=> M33w[|I1KGh? M2nGbIlv[3KnYYPld{B1cGViY1HNVEBt\X[nbIRCpC=> MYiyOVI3PjB4Mx?=
SK-N-AS  MUHGeY5kfGmxbjDBd5NigQ>? M1PSXFExKM7:TdMg M1:2OFI1KGh? M1rZ[4lv[3KnYYPld{B1cGViZYjwdoV{e2mxbjDv[kBkgWOuaX6gSFE> NUDNdZBtOjV{Nk[wOlM>
SK-N-AS  NHjpdIlHfW6ldHnvckBCe3OjeR?= NULITo9UOTBizszNxsA> NWmxSGV6OzBibXnu MXXpcoR2[2W|IIDoc5NxcG:{eXzheIlwdiCxZjFOtk1k[XSnbnnuJEh{\XJ4N{WpMEBxNUeVS{ROtkApe2W{OTmgZY5lKGOxbnPvcYl1[W62IHjp[4hmeiCuZY\lcJMhd2ZiYXP0bZZmNCC3boDoc5NxcG:{eXzheIVlNCEQsj3jZZRmdmmw M1Xz[FI2OjZ4ME[z
SK-N-AS  M{LlZmZ2dmO2aX;uJGF{e2G7 NXXVSmd2OTBizszNxsA> NH3DPWEyOC9|MD:2NEBucW5? MonVbY5kemWjc3XzJIxmfmWuczDv[kBxNc7{LXPheIVvcW5iKIPldlY4PSliYX7kJIlv\HWlZYOgZYNkfW23bHH0bY9vKG:oIICt{tIu[2G2ZX7pckApe2W{Nke1LUBqdiBqcHXybUlvfWOuZXHyJJJm\2mxboO= NHfsRWgzPTJ4NkC2Ny=>
SK-N-SH Mmr5R4VtdCCYaXHibYxqfHliQYPzZZk> Ml\ENVAh|ryPwrC= NY[5eG1XPDhiaB?= M{DaTIVvcGGwY3XzJHNMNU5vU1igcoV2em:kbHHzeI9u[SClZXzsJJZq[WKrbHn0fS=> MYGyOVI3PjB4Mx?=
HEK‐CFTR MYfGeY5kfGmxbjDBd5NigQ>? M4X1WFLjiJN3MNMg{txO NXfZVVZ1OC1zMjDtbY4> MYrEUXNQyqB? NUWwXWpucW6mdXPld{BiKGSxc3ZihLBl\XCnbnTlcpQhcW:maXTlJIVn\my3eNMg NYrFSolnOjV{NkOyNFc>
L6 NYizc4Z1TnWwY4Tpc44hSXO|YYm= MXq0NEDDvU1? MmGzNlQhcA>? MlfVbY5pcWKrdIOgSG1JOS2rbnT1Z4VlKEGtdDDhZ5RqfmG2aX;u NXv6ZXJSOjV{NEe1OVA>
MIN6  NWfUZXVkTnWwY4Tpc44hSXO|YYm= M{fue|ExKM7:TdMg NHrQXok{KGh? NEnh[lJqdmO{ZXHz[ZMhTDNibWLORUBmgHC{ZYPzbY9v NEnSR5MzPTJ2MUGyOC=>
ventricular cardiomyocytes  MnjDSpVv[3Srb36gRZN{[Xl? NIOyZngxNjBzLUGwJO69VQ>? NUDrU2hVcW6lcnXhd4V{KCClQV3QJIFk[3WvdXzheIlwdg>? NHHHUVAzPTJyM{GxNy=>
ventricular cardiomyocytes  NEPNSJFHfW6ldHnvckBCe3OjeR?= M13NTFAvODFvMUCg{txO MVfleo9s\XNiYX6gbY5wfHKxcHnjJJJme3CxboPlJFEzOMLzMUWlJIFjd3[nIHLhd4FtKHerdHigZY4hTUN3MNMgc4YhOi5{INM1US=> NILMUXAzPTJyM{GxNy=>
BeWo  MV;GeY5kfGmxbjDBd5NigQ>? NIW0OnUzOCEEtV2= NWKwemN[PDhiaB?= NEmx[W1FVVORwrC= M1uzU4lv\HWlZYOgZ4VtdCCodYPpc44> NUTCTmE1OjVzOES0O|c>
THP-1  NXvzVHZZTnWwY4Tpc44hSXO|YYm= NHvTS4oyNzFyIN88US=> NWTiVGhwOsLiaB?= NHj2fmpFVVORwrC= NVr4NYFTe3WycILld5NmeyCPQ2CtNUBxem:mdXP0bY9vyqB? MVKyOVE2PDh6Mh?=
Huh-7 MlHPSpVv[3Srb36gRZN{[Xl? NUXLZ2djOC1{MDFOwG0> MlnmNkBpyqB? NHHlfodz\XO3bITzJIlvKGFiZH;z[U1l\XCnbnTlcpQhcW6lcnXhd4UhcW5iYz3NfYMh\XiycnXzd4lwdiCjdDD0bIUheHKxdHXpckBidmRibWLORUBt\X[nbIO= MnjONlUyODl6M{S=
C6 M3vBOGZ2dmO2aX;uJGF{e2G7 MVWxNEDPxE4EoB?= MmjnNlAhdWmw M{\lZYlv[3KnYYPld{BkSU2SIHHjZ5VufWyjdHnvci=> NYf0[JYzOjVyNkm0NVc>
SW480 M2Xhc2Z2dmO2aX;uJGF{e2G7 M33vdVQxyqEQvF2= M4HhVFQ5yqCq NEnxUXlFVVOR MUXhZ5RqfmG2ZYOgVHAzSQ>? NUS2VWlVOjR7OUe0OVE>
HT-29  MV3GeY5kfGmxbjDBd5NigQ>? NUnsSWNHPDEEoN88US=> M{nwNFQ5yqCq MYLEUXNQ M1W2doFkfGm4YYTld{BRWDKD Mmj5NlQ6QTd2NUG=
SW480 NW\pfFMyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEHlblg1OMLizszN NXLVWXRlOC15MjDo NHnNRZBFVVOR MmHjbY5pcWKrdIOgZ4VtdCCpcn;3eIghfGmvZTDk[ZBmdmSnboTsfS=> MWKyOFk6PzR3MR?=
HT-29  M2raeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV\Zc21jPDEEoN88US=> NVqwZYNsOC15MjDo NWD2cXBUTE2VTx?= MYjpcohq[mm2czDj[YxtKGe{b4f0bEB1cW2nIHTldIVv\GWwdHz5 NYTFZm5pOjR7OUe0OVE>
SW480 MnrRSpVv[3Srb36gRZN{[Xl? MkK2OFDDqM7:TR?= NH7JNmQ4KGR? MWTEUXNQ Mmi3doVlfWOnczDjc4xwdm:|cHjldoUh\m:{bXH0bY9vKGOjcHHibYxqfHoEoB?= MYeyOFk6PzR3MR?=
HT-29  NFi1dnBHfW6ldHnvckBCe3OjeR?= MknhOFDDqM7:TR?= M{XZc|ch\A>? MmixSG1UVw>? M1:0S5Jm\HWlZYOgZ49td26xc4Do[ZJmKG[xcn3heIlwdiClYYDhZoltcXS7wrC= NF\5T2kzPDl7N{S1NS=>
SW480 NIOzcHJCeG:ydH;zbZMhSXO|YYm= NFLlW5g1OMLizszN MmP0OFjDqGh? NInC[|VFVVOR M{\B[4lv\HWlZYOgZY4h[WO2aY\heIlwdiCxZjDjZZNx[XOnIEOvOy=> NF7Y[3ozPDl7N{S1NS=>
HT-29  NE\hNnRCeG:ydH;zbZMhSXO|YYm= MmjzOFDDqM7:TR?= M1nYflQ5yqCq NXrBRlRjTE2VTx?= M{DaWYlv\HWlZYOgZY4h[WO2aY\heIlwdiCxZjDjZZNx[XOnIEOvOy=> M3jhVlI1QTl5NEWx
SW480 NHzlb41CeG:ydH;zbZMhSXO|YYm= NWexO28zPDEEoN88US=> NV3O[VNSPDkEoHi= Ml24SG1UVw>? NWC2dHdGcW6mdXPld{BkcGGwZ3XzJIlvKHSqZTDwbI9{eGixconsZZRqd25ic4TheJV{KG:oIGDQNmEhfGG{Z3X0dy=> NULlcYhqOjR7OUe0OVE>
HT-29  NIfjV4tCeG:ydH;zbZMhSXO|YYm= NUe0[FRmPDEEoN88US=> NXrwcmoxPDkEoHi= NGjkbopFVVOR MnLvbY5lfWOnczDjbIFv\2W|IHnuJJRp\SCyaH;zdIhwenmuYYTpc44he3SjdIXzJI9nKFCSMlGgeIFz\2W2cx?= NHHreoozPDl7N{S1NS=>

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

お薦めの試験操作(参考用のみ)

溶解度 (25°C)

体外 DMSO 82 mg/mL (199.75 mM)
Ethanol 37 mg/mL (90.13 mM)
Water Insoluble

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 410.5
化学式

C22H34O7

CAS No. 66575-29-9
保管
in solvent
別名 Coleonol

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (g) = 濃度 (mol/L) x 体積 (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01254006 Completed Glaucoma University of Roma La Sapienza|vingolo enzo maria|domanico daniela|salvatore serena null Not Applicable

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

cAMPシグナル伝達経路

Tags: Forskolinを買う | Forskolin ic50 | Forskolin供給者 | Forskolinを購入する | Forskolin費用 | Forskolin生産者 | オーダーForskolin | Forskolin化学構造 | Forskolin分子量 | Forskolin代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID